Alex Azar @SecAzar
Favoring high-rebate drugs over low-cost #biosimilars prevents the development of a robust biosimilars market, and costs seniors and taxpayers more. Our rebate rule would fix parts of the drug pricing system—like rebate walls—that create perverse incentives for patients. https://t.co/rT6Mk4D0IB — PolitiTweet.org